Unknown

Dataset Information

0

A human endothelial cell-based recycling assay for screening of FcRn targeted molecules.


ABSTRACT: Albumin and IgG have remarkably long serum half-lives due to pH-dependent FcRn-mediated cellular recycling that rescues both ligands from intracellular degradation. Furthermore, increase in half-lives of IgG and albumin-based therapeutics has the potential to improve their efficacies, but there is a great need for robust methods for screening of relative FcRn-dependent recycling ability. Here, we report on a novel human endothelial cell-based recycling assay (HERA) that can be used for such pre-clinical screening. In HERA, rescue from degradation depends on FcRn, and engineered ligands are recycled in a manner that correlates with their half-lives in human FcRn transgenic mice. Thus, HERA is a novel cellular assay that can be used to predict how FcRn-binding proteins are rescued from intracellular degradation.

SUBMITTER: Grevys A 

PROVIDER: S-EPMC5809500 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


Albumin and IgG have remarkably long serum half-lives due to pH-dependent FcRn-mediated cellular recycling that rescues both ligands from intracellular degradation. Furthermore, increase in half-lives of IgG and albumin-based therapeutics has the potential to improve their efficacies, but there is a great need for robust methods for screening of relative FcRn-dependent recycling ability. Here, we report on a novel human endothelial cell-based recycling assay (HERA) that can be used for such pre-  ...[more]

Similar Datasets

| S-EPMC4625676 | biostudies-literature
| S-EPMC3060295 | biostudies-literature
| S-EPMC5576216 | biostudies-literature
| S-EPMC2850055 | biostudies-literature
| S-EPMC5356901 | biostudies-other
| S-EPMC4476654 | biostudies-literature
| S-EPMC5228278 | biostudies-literature
| S-EPMC3727932 | biostudies-literature
| S-EPMC4326836 | biostudies-literature
| S-EPMC7098380 | biostudies-literature